215 related articles for article (PubMed ID: 30456574)
1. CCR5 blockage by maraviroc: a potential therapeutic option for metastatic breast cancer.
Pervaiz A; Zepp M; Mahmood S; Ali DM; Berger MR; Adwan H
Cell Oncol (Dordr); 2019 Feb; 42(1):93-106. PubMed ID: 30456574
[TBL] [Abstract][Full Text] [Related]
2. Antineoplastic effects of targeting CCR5 and its therapeutic potential for colorectal cancer liver metastasis.
Pervaiz A; Zepp M; Georges R; Bergmann F; Mahmood S; Faiza S; Berger MR; Adwan H
J Cancer Res Clin Oncol; 2021 Jan; 147(1):73-91. PubMed ID: 32902795
[TBL] [Abstract][Full Text] [Related]
3. The CCR5 antagonist maraviroc causes remission of pancreatic cancer liver metastasis in nude rats based on cell cycle inhibition and apoptosis induction.
Huang H; Zepp M; Georges RB; Jarahian M; Kazemi M; Eyol E; Berger MR
Cancer Lett; 2020 Apr; 474():82-93. PubMed ID: 31954769
[TBL] [Abstract][Full Text] [Related]
4. CCR5 blockage by maraviroc induces cytotoxic and apoptotic effects in colorectal cancer cells.
Pervaiz A; Ansari S; Berger MR; Adwan H
Med Oncol; 2015 May; 32(5):158. PubMed ID: 25840792
[TBL] [Abstract][Full Text] [Related]
5. Asperolide A prevents bone metastatic breast cancer via the PI3K/AKT/mTOR/c-Fos/NFATc1 signaling pathway.
Jiang W; Rixiati Y; Huang H; Shi Y; Huang C; Jiao B
Cancer Med; 2020 Nov; 9(21):8173-8185. PubMed ID: 32976685
[TBL] [Abstract][Full Text] [Related]
6. CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth.
Casagrande N; Borghese C; Visser L; Mongiat M; Colombatti A; Aldinucci D
Haematologica; 2019 Mar; 104(3):564-575. PubMed ID: 30309853
[TBL] [Abstract][Full Text] [Related]
7. Essential roles of the interaction between cancer cell-derived chemokine, CCL4, and intra-bone CCR5-expressing fibroblasts in breast cancer bone metastasis.
Sasaki S; Baba T; Nishimura T; Hayakawa Y; Hashimoto S; Gotoh N; Mukaida N
Cancer Lett; 2016 Aug; 378(1):23-32. PubMed ID: 27177471
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis.
Jin K; Pandey NB; Popel AS
Breast Cancer Res; 2018 Jun; 20(1):54. PubMed ID: 29898755
[TBL] [Abstract][Full Text] [Related]
9. Cellular effect of styrene substituted biscoumarin caused cellular apoptosis and cell cycle arrest in human breast cancer cells.
Perumalsamy H; Sankarapandian K; Kandaswamy N; Balusamy SR; Periyathambi D; Raveendiran N
Int J Biochem Cell Biol; 2017 Nov; 92():104-114. PubMed ID: 28958615
[TBL] [Abstract][Full Text] [Related]
10. Antitumor Effects of Ruyiping on Cell Growth and Metastasis in Breast Cancer.
Li Z; Sun X; Liu X; Sun Z; Li J
Cancer Biother Radiopharm; 2019 Jun; 34(5):297-305. PubMed ID: 30901274
[No Abstract] [Full Text] [Related]
11. Chemokine C-C motif receptor 5 and C-C motif ligand 5 promote cancer cell migration under hypoxia.
Lin S; Wan S; Sun L; Hu J; Fang D; Zhao R; Yuan S; Zhang L
Cancer Sci; 2012 May; 103(5):904-12. PubMed ID: 22380870
[TBL] [Abstract][Full Text] [Related]
12. An agent-based model of triple-negative breast cancer: the interplay between chemokine receptor CCR5 expression, cancer stem cells, and hypoxia.
Norton KA; Wallace T; Pandey NB; Popel AS
BMC Syst Biol; 2017 Jul; 11(1):68. PubMed ID: 28693495
[TBL] [Abstract][Full Text] [Related]
13. Naringenin inhibits migration of breast cancer cells via inflammatory and apoptosis cell signaling pathways.
Zhao Z; Jin G; Ge Y; Guo Z
Inflammopharmacology; 2019 Oct; 27(5):1021-1036. PubMed ID: 30941613
[TBL] [Abstract][Full Text] [Related]
14. CCR5/CCL5 axis interaction promotes migratory and invasiveness of pancreatic cancer cells.
Singh SK; Mishra MK; Eltoum IA; Bae S; Lillard JW; Singh R
Sci Rep; 2018 Jan; 8(1):1323. PubMed ID: 29358632
[TBL] [Abstract][Full Text] [Related]
15. In vitro effects of the CCR5 inhibitor maraviroc on human T cell function.
Arberas H; Guardo AC; Bargalló ME; Maleno MJ; Calvo M; Blanco JL; García F; Gatell JM; Plana M
J Antimicrob Chemother; 2013 Mar; 68(3):577-86. PubMed ID: 23152485
[TBL] [Abstract][Full Text] [Related]
16. A novel antagonist of the CCL5/CCR5 axis suppresses the tumor growth and metastasis of triple-negative breast cancer by CCR5-YAP1 regulation.
Chen L; Xu G; Song X; Zhang L; Chen C; Xiang G; Wang S; Zhang Z; Wu F; Yang X; Zhang L; Ma X; Yu J
Cancer Lett; 2024 Feb; 583():216635. PubMed ID: 38237887
[TBL] [Abstract][Full Text] [Related]
17. Evodiamine induces apoptosis and inhibits metastasis in MDA‑MB-231 human breast cancer cells in vitro and in vivo.
Du J; Wang XF; Zhou QM; Zhang TL; Lu YY; Zhang H; Su SB
Oncol Rep; 2013 Aug; 30(2):685-94. PubMed ID: 23708383
[TBL] [Abstract][Full Text] [Related]
18. CR5/CCL5 axis is linked to a poor outcome, and inhibition reduces metastasis in oral squamous cell carcinoma.
González-Arriagada WA; Coletta RD; Lozano-Burgos C; García C; Maripillán J; Alcayaga-Miranda F; Godínez-Pacheco B; Oyarce-Pezoa S; Martínez-Flores R; García IE
J Cancer Res Clin Oncol; 2023 Dec; 149(19):17335-17346. PubMed ID: 37831273
[TBL] [Abstract][Full Text] [Related]
19. Riproximin modulates multiple signaling cascades leading to cytostatic and apoptotic effects in human breast cancer cells.
Pervaiz A; Zepp M; Adwan H; Berger MR
J Cancer Res Clin Oncol; 2016 Jan; 142(1):135-47. PubMed ID: 26163990
[TBL] [Abstract][Full Text] [Related]
20. Up-regulation of bone marrow stromal protein 2 (BST2) in breast cancer with bone metastasis.
Cai D; Cao J; Li Z; Zheng X; Yao Y; Li W; Yuan Z
BMC Cancer; 2009 Apr; 9():102. PubMed ID: 19338666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
